- Home
- CRDF vs BDTX Comparison
CRDF vs BDTX Comparison
Compare CRDF & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- BDTX
- Stock Information
- Founded
- CRDF 1999
- BDTX 2014
- Country
- CRDF United States
- BDTX United States
- Employees
- CRDF N/A
- BDTX N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRDF Health Care
- BDTX Health Care
- Exchange
- CRDF Nasdaq
- BDTX Nasdaq
- Market Cap
- CRDF 133.5M
- BDTX 144.9M
- IPO Year
- CRDF N/A
- BDTX 2020
- Fundamental
- Price
- CRDF $4.96
- BDTX $2.53
- Analyst Decision
- CRDF Strong Buy
- BDTX Strong Buy
- Analyst Count
- CRDF 3
- BDTX 4
- Target Price
- CRDF $10.33
- BDTX $15.50
- AVG Volume (30 Days)
- CRDF 3.9M
- BDTX 476.4K
- Earning Date
- CRDF 11-07-2024
- BDTX 11-05-2024
- Dividend Yield
- CRDF N/A
- BDTX N/A
- EPS Growth
- CRDF N/A
- BDTX N/A
- EPS
- CRDF N/A
- BDTX N/A
- Revenue
- CRDF $688,000.00
- BDTX N/A
- Revenue This Year
- CRDF $23.78
- BDTX N/A
- Revenue Next Year
- CRDF N/A
- BDTX N/A
- P/E Ratio
- CRDF N/A
- BDTX N/A
- Revenue Growth
- CRDF 49.57
- BDTX N/A
- 52 Week Low
- CRDF $1.30
- BDTX $2.31
- 52 Week High
- CRDF $6.42
- BDTX $7.66
- Technical
- Relative Strength Index (RSI)
- CRDF 72.82
- BDTX 43.96
- Support Level
- CRDF $3.06
- BDTX $2.43
- Resistance Level
- CRDF $5.64
- BDTX $2.66
- Average True Range (ATR)
- CRDF 0.45
- BDTX 0.16
- MACD
- CRDF 0.29
- BDTX 0.05
- Stochastic Oscillator
- CRDF 84.32
- BDTX 48.81
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.